Shilpa Medicare gets Code J for Pemetrexed Injection
Shilpa's - NDA Pemetrexed Injection, is a novel ready-to-use injection which eliminates the need for reconstitution and dilution before administration to the patient.
Karnataka: Shilpa Medicare has announced that the Company's NDA Product PEMRYDI RTU (Pemetrexed injection 10 mg/mL), has received from the U.S. Centers for Medicare & Medicaid Services (CMS) an exclusive product-specific code J.
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents. It is also indicated in the treatment of mesothelioma in combination with cisplatin and has market size of US $ 293 million as per IQVIA MAT Q3 2023.
Shilpa’s - NDA Pemetrexed Injection, is a novel ready-to-use injection which eliminates the need for reconstitution and dilution before administration to the patient. This ready-to-use formulation enables reduction of dosing errors, ease of administration and accurate dosing based on patient body weight.
J-codes are permanent reimbursement codes used by healthcare providers, government payers and commercial insurers to facilitate billing of Medicare Part B treatments, which must be administered by a healthcare professional. J-codes simplify and streamline the billing and reimbursement processes, allowing for efficient claims processing resulting in significant conveniences to the patient. Code “J” enables marketing the product as a niche product.
Shilpa has already signed with the US partner for launching this product in the US market and will be launched in Q-1 of 2024.
Read also: Shilpa Medicare Jadcherla facility clears TGA, Australia GMP inspection
Shilpa Medicare Limited, headquartered at Raichur, Karnataka, India, is a vertically integrated, manufacturer and distributor of quality drugs to global markets; specializing in the Oncology therapeutic segment.
